Physician profile
Robert S Auerbach
NPI 1861478034
$801.88
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $140 · 2022: $19.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $253.63 | 2019-2020 | |
| Amgen INC. | $215.43 | 2019-2020 | |
| Radius Health, INC. | $101.06 | 2019-2020 | |
| Avion Pharmaceuticals | $46.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.24 | 2019-2020 | |
| Lupin INC. | $26.04 | 2019 | |
| Daiichi Sankyo INC. | $24.58 | 2019 | |
| Therapeuticsmd, INC. | $20.87 | 2020 | |
| Boston Scientific Corporation | $19.08 | 2022 | |
| Duchesnay USA Incorporated | $16.29 | 2019 | |
| Exeltis, USA INC. | $14.09 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.99 | 2019 | |
| Astellas Pharma US INC | $11.28 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Auerbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.